Abstract:Glioblastoma (GBM) is the most common malignant primary tumor in the human central nervous system. The present study aimed to explore the molecular mechanism by which microRNA (miR)-181a-5p targets the F-box protein 11 (FBXO11) in glioma cells to inhibit cell proliferation and invasion. Reverse transcription-quantitative (RT-q)PCR was performed to detect the expression levels of miR-181a-5p in U251TR cells, U251 cells, primary GBM tissues and relapsed GBM tissues in order to determine the association between miR-181a-5p and the chemoresistance of GBM cells. The expression levels of miR-181a-5p in GBM cells were modulated via transfecting miR-181a-5p mimics and inhibitors. Cell Counting Kit-8 assays were undertaken to assess the effects of miR-181a-5p on drug sensitivity and proliferation of GBM cells. Wound healing assays were performed to examine the effects of miR-181a-5p on the migratory ability of GBM cells. Furthermore, the effects of miR-181a-5p on the invasive ability of GBM cells were analyzed using an in vitro invasion assay. Flow cytometry analysis was carried out to determine whether overexpression of miR-181a-5p can promote the apoptotic rate of GBM cells. RT-qPCR and western blotting were employed to detect the effects of miR-181a-5p on mRNA and protein expression of FBX011. miR-181a-5p exhibited low expression in resistant GBM cell lines and recurrent tumor tissues. Dual-luciferase reporter assays were utilized to detect luciferase activity to verify the targeted regulatory association between miR-181a-5p and FBXO11. Upregulation of miR-181a-5p promoted the sensitivity of GBM cells to temozolomide (TMZ), increased the apoptotic rate of GBM cells and significantly inhibited the invasive and migratory capacities of GBM cells. In drug-resistant glioma cells, compared with the miR-negative control group and the blank group, the expression of miR-181a-5p was significantly upregulated (P<0.01), while the expression of FBXO11 protein was downregulated. miR-181a-5p increased the sensitivity of GBM cells to TMZ. miR-181a-5p significantly inhibited the migratory and invasive capacities of GBM cells. miR-181a-5p may become a novel effective target for the treatment of GBM. The results of dual-luciferase reporter assays indicated that miR-181a-5p could target the 3'-untranslated region of FBXO11. The underlying mechanism may be targeted inhibition of FBXO11 gene expression, or may be associated with apoptosis.

miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1

MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2

miR-9-5p Mediates ABCC1 to Elevate the Sensitivity of Glioma Cells to Temozolomide

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells

miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma

miR-92b-3p Regulates Cell Progression and Drug Resistance through Upregulation of CXCL5 in Glioma

miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells

Mir-146B-5p Suppresses Glioblastoma Cell Resistance to Temozolomide Through Targeting TRAF6

Mir-181A-5p Inhibits the Proliferation and Invasion of Drug-Resistant Glioblastoma Cells by Targeting F-box Protein 11 Expression

MicroRNA-144 Represses Gliomas Progression and Elevates Susceptibility to Temozolomide by Targeting CAV2 and FGF7

Knockdown of RLIP76 expression by RNA interference inhibits invasion, induces cell cycle arrest, and increases chemosensitivity to the anticancer drug temozolomide in glioma cells

MiR-21 Protected Human Glioblastoma U87MG Cells from Chemotherapeutic Drug Temozolomide Induced Apoptosis by Decreasing Bax/Bcl-2 Ratio and Caspase-3 Activity

Exosomal Transfer of Mir‑25‑3p Promotes the Proliferation and Temozolomide Resistance of Glioblastoma Cells by Targeting FBXW7.

Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy

Up-Regulation of Mir-497 Confers Resistance to Temozolomide in Human Glioma Cells by Targeting Mtor/Bcl-2

LINC00470 Promotes Tumour Proliferation and Invasion, and Attenuates Chemosensitivity Through the LINC00470/miR-134/Myc/ABCC1 Axis in Glioma.

miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.

MiR‐223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway